[ACN Newswire] – By David MoskowitzWe continue to believe that shares of Elan Corp. (NYSE:ELN) are trading at a premium valuation, given ongoing speculation that partner Biogen-Idec (NASDAQ:BIIB) may acquire the company … moreView todays social media effects on ELNView the latest stocks trending across Twitter. Click to view dashboard […]
[ACN Newswire] – By David MoskowitzWe have written about the pressure on shares of Elan Corp. (NYSE:ELN), which has been taking place in advance of the expected market entry of Biogen Idec’s (NASDAQ:BIIB) BG-12 treatment … moreView todays social media effects on ELNView the latest stocks trending across Twitter. Click to view dashboard […]
[ACN Newswire] – By Jake KingElan Corp. (NYSE:ELN) is facing headwinds Monday morning after an analyst downgraded the stock based on slowing Tysabri sales growth. Leerink Swann lowered ELN’s price target from $12 to $8 … moreView todays social media effects on ELNView the latest stocks trending across Twitter. Click to view dashboard […]
[ACN Newswire] – By David MoskowitzWith Biogen-Idec’s (NASDAQ:BIIB) new multiple sclerosis (MS) treatment, BG-12, approaching a decision by the FDA (PDUFA date December 28th), enthusiasm in the medical community is building … moreView todays social media effects on ELNView the latest stocks trending across Twitter. Click to view dashboard […]
